Individualized dosimetry-based activity reduction of 90 Y-DOTATOC prevents severe and rapid kidney function deterioration from peptide receptor radionuclide therapy

Purpose Assessment of kidney function evolution after 90Y-DOTATOC peptide receptor radionuclide therapy (PRRT) with capped activity administration based on a 37-Gy threshold of biological effective dose (BED) to the kidney.